Cargando…

Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition

BET family proteins are novel therapeutic targets for cancer and inflammation and represent the first chromatin readers against which small-molecule inhibitors have been developed. First-generation BET inhibitors have shown therapeutic efficacy in preclinical models, but the consequences of sustaine...

Descripción completa

Detalles Bibliográficos
Autores principales: Bolden, Jessica E., Tasdemir, Nilgun, Dow, Lukas E., van Es, Johan H., Wilkinson, John E., Zhao, Zhen, Clevers, Hans, Lowe, Scott W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234106/
https://www.ncbi.nlm.nih.gov/pubmed/25242322
http://dx.doi.org/10.1016/j.celrep.2014.08.025
_version_ 1782344799313985536
author Bolden, Jessica E.
Tasdemir, Nilgun
Dow, Lukas E.
van Es, Johan H.
Wilkinson, John E.
Zhao, Zhen
Clevers, Hans
Lowe, Scott W.
author_facet Bolden, Jessica E.
Tasdemir, Nilgun
Dow, Lukas E.
van Es, Johan H.
Wilkinson, John E.
Zhao, Zhen
Clevers, Hans
Lowe, Scott W.
author_sort Bolden, Jessica E.
collection PubMed
description BET family proteins are novel therapeutic targets for cancer and inflammation and represent the first chromatin readers against which small-molecule inhibitors have been developed. First-generation BET inhibitors have shown therapeutic efficacy in preclinical models, but the consequences of sustained BET protein inhibition in normal tissues remain poorly characterized. Using an inducible and reversible transgenic RNAi mouse model, we show that strong suppression of the BET protein Brd4 in adult animals has dramatic effects in multiple tissues. Brd4-depleted mice display reversible epidermal hyperplasia, alopecia, and decreased cellular diversity and stem cell depletion in the small intestine. Furthermore, Brd4-suppressed intestines are sensitive to organ stress and show impaired regeneration following irradiation, suggesting that concurrent Brd4 suppression and certain cytotoxic therapies may induce undesirable synergistic effects. These findings provide important insight into Brd4 function in normal tissues and, importantly, predict several potential outcomes associated with potent and sustained BET protein inhibition.
format Online
Article
Text
id pubmed-4234106
institution National Center for Biotechnology Information
language English
publishDate 2014
record_format MEDLINE/PubMed
spelling pubmed-42341062014-11-17 Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition Bolden, Jessica E. Tasdemir, Nilgun Dow, Lukas E. van Es, Johan H. Wilkinson, John E. Zhao, Zhen Clevers, Hans Lowe, Scott W. Cell Rep Article BET family proteins are novel therapeutic targets for cancer and inflammation and represent the first chromatin readers against which small-molecule inhibitors have been developed. First-generation BET inhibitors have shown therapeutic efficacy in preclinical models, but the consequences of sustained BET protein inhibition in normal tissues remain poorly characterized. Using an inducible and reversible transgenic RNAi mouse model, we show that strong suppression of the BET protein Brd4 in adult animals has dramatic effects in multiple tissues. Brd4-depleted mice display reversible epidermal hyperplasia, alopecia, and decreased cellular diversity and stem cell depletion in the small intestine. Furthermore, Brd4-suppressed intestines are sensitive to organ stress and show impaired regeneration following irradiation, suggesting that concurrent Brd4 suppression and certain cytotoxic therapies may induce undesirable synergistic effects. These findings provide important insight into Brd4 function in normal tissues and, importantly, predict several potential outcomes associated with potent and sustained BET protein inhibition. 2014-09-18 2014-09-25 /pmc/articles/PMC4234106/ /pubmed/25242322 http://dx.doi.org/10.1016/j.celrep.2014.08.025 Text en ©2014 The Authors This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0).
spellingShingle Article
Bolden, Jessica E.
Tasdemir, Nilgun
Dow, Lukas E.
van Es, Johan H.
Wilkinson, John E.
Zhao, Zhen
Clevers, Hans
Lowe, Scott W.
Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition
title Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition
title_full Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition
title_fullStr Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition
title_full_unstemmed Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition
title_short Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition
title_sort inducible in vivo silencing of brd4 identifies potential toxicities of sustained bet protein inhibition
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234106/
https://www.ncbi.nlm.nih.gov/pubmed/25242322
http://dx.doi.org/10.1016/j.celrep.2014.08.025
work_keys_str_mv AT boldenjessicae inducibleinvivosilencingofbrd4identifiespotentialtoxicitiesofsustainedbetproteininhibition
AT tasdemirnilgun inducibleinvivosilencingofbrd4identifiespotentialtoxicitiesofsustainedbetproteininhibition
AT dowlukase inducibleinvivosilencingofbrd4identifiespotentialtoxicitiesofsustainedbetproteininhibition
AT vanesjohanh inducibleinvivosilencingofbrd4identifiespotentialtoxicitiesofsustainedbetproteininhibition
AT wilkinsonjohne inducibleinvivosilencingofbrd4identifiespotentialtoxicitiesofsustainedbetproteininhibition
AT zhaozhen inducibleinvivosilencingofbrd4identifiespotentialtoxicitiesofsustainedbetproteininhibition
AT clevershans inducibleinvivosilencingofbrd4identifiespotentialtoxicitiesofsustainedbetproteininhibition
AT lowescottw inducibleinvivosilencingofbrd4identifiespotentialtoxicitiesofsustainedbetproteininhibition